Most Active Stocks to Run: GoPro Inc (GPRO), Pfizer Inc. (PFE)



Stock’s Trading Stats:

GoPro Inc (NASDAQ:GPRO) is trading up with a percentage change of 13.19% and is at $13.24 right now. The Company’s market capitalization stands at $1.80 Billion in the current trading Session whereas, its outstanding shares are 100.60 Million.

Recent Press Release:

At NAB 2016, April 18-21 in Las Vegas, GoPro (GPRO) will showcase Omni, its synchronized six-camera spherical array that produces high-resolution, stunning image quality. Proprietary hardware at the center of Omni facilitates pixel-level synchronization between all six HERO4 Blacks. Other features include:

  • Six Cameras that act as one
  • Proven image quality of the HERO4 Black…times six
  • GoPro Kolor software optimized

About GoPro, Inc. (GPRO) GoPro, Inc. is transforming the way people visually capture and share their lives. What began as an idea to assist athletes self-document themselves engaged in their sport, GoPro has become a standard for how people capture themselves engaged in their interests, whatever they may be. From extreme to mainstream, professional to consumer, GoPro facilitates the world to capture and share its passion in the form of immersive and engaging content.

Pfizer Inc. (NYSE:PFE)

Stock’s Trading Stats:

Pfizer Inc. (NYSE:PFE) is surging 1.35% percent and is at $32.40 in the Real-Time trading session. The stock’s market capitalization stands at $201.06 Billion with outstanding shares of 6.19 Billion.

Recent Press Release:

Pfizer Inc. (PFE), and IBM (IBM) on April 7, 2016 declared a first-of-its-kind research partnershipto develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate aim is to obtain a better understanding of a patient’s disease progression and medication response to assist inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options.

Parkinson’s disease in particular requires ongoing adjustment to medication depending on the progression of the disease and response of the patient. The partnershiplook fors to create a holistic view of a patient’s well-being by look foring to accurately measure various health indicators, counting motor function, dyskinesia, cognition, sleep and daily activities such as grooming, dressing and eating. Insights from these data could assist clinicians understand the effect of a patient’s medication as the disease progresses, enabling them to assist optimize the patient’s treatment regimen as needed. Data generated through the system could also arm researchers with the insights and real-world evidence needed to assist accelerate potential new and better therapies.